French company brings innovative pharmaceutical technologies to Kazakhstan

medicines-640×480-4b7

ASTANA (TCA) — French pharmaceutical company Servier and KAZAKH INVEST National Company for Investment Support and Promotion signed an agreement on cooperation in pharmaceutical production. The document was signed by Servier’s EAEU Managing Director Jerome Gavet and KAZAKH INVEST Chairman Saparbek Tuyakbayev, at the Kazakhstan Global Investment Roundtable in Astana on July 3, the Kazakh company said.

The day before, Kazakh Prime Minister Bakytzhan Sagintayev held a bilateral meeting with Servier’s representatives Jerome Gavet (EAEU Managing Director), Oleg Negulyaev (General Director of Servier Kazakhstan LLP) and Yana Kotukhova (Director for Government Relations and External Communications in the EAEU).

The parties discussed the possibility of transferring Servier’s innovative pharmaceutical technologies to Kazakhstan and agreed on coordination of the investment strategy for localization of medicines production. These agreements formed the basis for the Cooperation Agreement between Servier and KAZAKH INVEST.

“Development and strengthening of cooperation with Kazakhstan, where we have been operating for more than 20 years, is one of the priorities for Servier. We are discussing investment opportunities with the Government of Kazakhstan and have already had a series of fruitful negotiations and signed a Cooperation Agreement with KAZAKH INVEST JSC. We are ready to offer not only transfer of innovative technologies for production of original medicines, but also modern solutions to increase the effectiveness of treatment of chronic non-infectious diseases, such as cardiovascular diseases, diabetes, etc. I believe that the Cooperation Agreement is an important step towards increasing the availability of high-quality innovative solutions for the people of Kazakhstan,” said Servier’s EAEU Managing Director Jerome Gavet.

The next step in the bilateral relations will be to develop a road map to determine the stages and timeframes of the investment project on local production of Servier’s innovative medicines in Kazakhstan.

“The agreement with the French company Servier is one of the examples of attracting investments in high-tech projects. We hope that this cooperation will have a significant impact on the pharmaceutical market development in Kazakhstan,” said the Chairman of Kazakh Invest Saparbek Tuyakbaev.

The French pharmaceutical company and Kazakhstan have been cooperating for more than 20 years. Servier Group is currently in the TOP 15 companies in the Kazakhstan’s pharmaceutical market and a leading company in the field of cardiovascular diseases treatment.

Servier is an international pharmaceutical company managed by a non-profit foundation, headquartered in Suresnes, France. The company is represented in 148 countries on 5 continents and has more than 21 600 employees. Servier’s annual turnover in 2017 reached 4.152 billion Euros. The company’s high growth rate is a result of constant development and search for innovations in five key areas, such as diabetes, cardiovascular, oncological, immunoinflammatory and neurodegenerative diseases, and creation of high-quality generics.

Sergey Kwan

TCA